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Background Empirical research has illustrated an association between study size
and relative treatment effects, but conclusions have been inconsist-
ent about the association of study size with the risk of bias items.
Small studies give generally imprecisely estimated treatment effects,
and study variance can serve as a surrogate for study size.
Methods We conducted a network meta-epidemiological study analyzing 32
networks including 613 randomized controlled trials, and used
Bayesian network meta-analysis and meta-regression models to
evaluate the impact of trial characteristics and study variance on
the results of network meta-analysis. We examined changes in rela-
tive effects and between-studies variation in network meta-regres-
sion models as a function of the variance of the observed effect size
and indicators for the adequacy of each risk of bias item.
Adjustment was performed both within and across networks, allow-
ing for between-networks variability.
Results Imprecise studies with large variances tended to exaggerate the
effects of the active or new intervention in the majority of net-
works, with a ratio of odds ratios of 1.83 (95% CI: 1.09,3.32).
Inappropriate or unclear conduct of random sequence generation
and allocation concealment, as well as lack of blinding of patients
and outcome assessors, did not materially impact on the summary
results. Imprecise studies also appeared to be more prone to inad-
equate conduct.
Conclusions Compared to more precise studies, studies with large variance may
give substantially different answers that alter the results of network
meta-analyses for dichotomous outcomes.
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treatment comparison, small-study effects, publication bias
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Introduction
Empirical research has suggested that smaller stu-
dies tend to show larger treatment effects than do
larger studies.1–3 This phenomenon, known as the
small-study effect, can be partly explained by publi-
cation bias; small studies with non-significant treat-
ment effects are less likely to be published. Other
explanations for small-study effects, such as the as-
sociation between small study size and a lower
study quality that leads to overestimation of treat-
ment effects, very likely operate alone or in combin-
ation with publication bias. In the case of
randomized controlled trials (RCTs), allocation con-
cealment and blinding have been found to be im-
portant quality-related trial characteristics that can
influence the results of individual studies or meta-
analyses.4–6 This association was recently confirmed
by the largest such study to date,7 although the
strength of the association was found to be less
than in previous analyses.
Because both study size and variability in the treat-
ment effects among the individual patients within a
study may be associated with the magnitude of effect
estimates, statistical models exploring the effects of
these study characteristics usually use the precision
of the study summary estimates (or a function of
the precision, such as the standard error or variance)
as an explanatory factor. Several regression-based
methods have been proposed to model the relation-
ship between effect size and some measure of its pre-
cision or other study characteristics.1,8,9 These
methods require a sufficient number of available stu-
dies, and over a range of study characteristics, to esti-
mate the impact of study characteristics (represented
by a bias parameter) on the results of meta-analysis.10
For this reason, meta-epidemiological approaches,
which consider collections of independent meta-ana-
lyses and assume that the bias across these meta-
analyses is of comparable magnitude and direction,
are employed to increase the number of studies in
the analysis and improve the power of the ana-
lysis.5,10–12 However, the comparability of the bias
parameters across meta-analyses from different
fields of clinical research is often questionable.
Network meta-analysis is an extension of conven-
tional (pairwise) meta-analysis that synthesizes
evidence from systematic reviews that compare mul-
tiple treatments.13,14 Network meta-analysis data have
not yet been considered as a means for evaluating
bias in meta-epidemiological studies, although these
data arguably provide a larger evidence base upon
which to address such methodological questions.
First, systematic reviews aiming to compare multiple
treatments produce a network of comparisons for the
same outcome and population, and therefore provide
a natural pool of meta-epidemiological data for which
it could be assumed that bias is acting in a similar
way across trials that have similar characteristics.
Second, network meta-analysis is more powerful
than pairwise meta-analysis when adjustment is per-
formed for potentially biased effect sizes.15 Third, the
use of network meta-analysis in meta-epidemiology
(which we shall refer to as network meta-epidemi-
ology) to estimate bias parameters exploits the as-
sumption that bias parameters are more similar
across comparisons within the same treatment net-
work than they are across networks. The use of net-
work meta-epidemiology has been exemplified by
Salanti et al.16 The aim of the present paper is to
use network meta-epidemiology to determine the as-
sociation of trial characteristics (generation of alloca-
tion sequence, allocation concealment, blinding) with
treatment effects estimated in network meta-analysis
and their connection with study precision. For this
purpose, we use a collection of published networks
of treatments.
Methods
Selection of networks of interventions
We searched in PubMed for meta-analyses of RCTs
published by the end of March 2011 in which at
least three treatments were included and the data
had been analysed with a valid statistical method
for indirect comparisons or network meta-analysis
(also called multiple-treatments meta-analysis or
mixed-treatment comparison). We applied no restric-
tion regarding the type of outcome measure for the
individual studies (dichotomous, continuous, etc.),
nor for the effect sizes of meta-analyses (odds ratio
(OR), risk ratio (RR), mean difference (MD), etc.). To
evaluate the impact of the trial characteristics and
imprecise-study effects, we included only networks
in which all treatments were compared to a
common comparator (star-shaped networks). Such
networks do not have closed loops. The advantage
of using star-shaped networks is that the direction
of possible bias is expected to operate against the
common comparator, typically an inactive or older
standard treatment in each network’s field. We
excluded diagnostic test accuracy studies and net-
works in which the number of treatments was greater
than the number of trials (networks with sparse in-
formation). To further investigate the presence of im-
precise-study effects, we enriched the database with
full networks (which include closed loops) of at least
four treatments that involved an obvious reference
intervention. Details of the search code can be
found in the Supplementary Appendix, available as
Supplementary data at IJE online.
Data extraction
From every published paper included in our study, we
extracted the method used for the indirect compari-
son, as well as the number of studies and interven-
tions and data for the primary outcome (or, if this
was not specified, the outcome presented first in the
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meta-analysis). If outcome data or risk of bias infor-
mation were not available, we contacted the authors.
Arm-level data were preferred to study-level data17
when both were reported; a mixture of both was
used if some studies reported trial-level and some re-
ported arm-level data.18 Two authors independently
assessed the risk of bias in all RCTs of all included
networks for which risk of bias data were not avail-
able either in the publication or from the authors
upon request. Based on the Cochrane Risk of Bias
Tool,19 we sought information regarding the random
sequence generation, allocation concealment, and
blinding of patients and outcome assessors. For each
item, studies were classified into the three groups;
being at low, unclear, or high risk of bias.
Statistical analysis
We analysed all included star-shaped networks using
standard Bayesian network meta-analysis models.14,15
These models assume consistency in the estimated
effect sizes. This means that if z,c is the effect of
treatment c vs. the reference treatment (the
common comparator) in star network z, and z,j is
the effect of j vs. the reference, then the effect of c
vs. j is z,cj ¼ z,c  z,j. We used a random effects
model that allows for between-study variation in the
estimated effect sizes and a common heterogeneity
variance (2z ) for all comparisons in a network z.
To account for the impact of trial characteristics and
imprecise-study effects, we employed network meta-re-
gression models.20,21 We used an indicator variable to
represent each bias item (categorized as low risk
vs. high or unclear risk) and the variance of the
observed effect size22 to represent an imprecise-study
effect (studies with treatment effects with large vari-
ances). Adjustment can take place both on models for
study-level or arm-level data (a detailed description is
given in the Supplementary Appendix).
To ensure enough power to perform meta-regres-
sion, we initially assessed the effects of each risk of
bias item and study precision in separate meta-regres-
sion models within each star-shaped network
(indexed with z) that included at least 10 studies.23
We re-expressed each covariate so that for both harm-
ful and beneficial outcomes a positive regression co-
efficient, , indicated that less precise studies or
studies at unclear or high risk of bias overestimated
the effectiveness or safety of each treatment com-
pared to the reference treatment. We used the
enriched database (including the full networks) to
perform sensitivity analysis for the investigation of
imprecise-study effects and we estimated the regres-
sion coefficient for each full network assuming impre-
cise head-to-head trials have no impact on the results.
We first assumed that the impact of trial character-
istics was identical for each comparison of a treat-
ment k with the reference treatment within the
same network (i.e. that z,k ¼ Bz (a single fixed-
effect coefficient)). As sensitivity analyses, we
assumed that regression coefficients z,k were differ-
ent yet exchangeable across comparisons within the
same network, by sharing a normal distribution with
a common mean, Bz, and variance 
2
z , with the latter
expressing the variability between the coefficients in
the same network.
In the network meta-epidemiological model, we
linked the network-specific coefficients across net-
works into a ‘joint model.’16 This allowed networks
with few studies to borrow strength from those with
more studies, and increased the power of the analysis
while yielding an estimated overall coefficient, Boverall.
We allowed for between-networks variability by
assuming Bz  N Boverall, !2
 
, and in a sensitivity ana-
lysis we fitted a common (fixed) coefficient across
networks (Bz ¼ Boverall). The network meta-epidemio-
logical model linked only networks estimating out-
comes using the same effect size measure [for
dichotomous outcomes the OR, for continuous out-
comes the MD and for survival the hazard ratio
(HR)]; networks with different effect size measures
were excluded from this analysis. For dichotomous
outcomes, the association is presented as the ratio
of ORs (ROR), which is the exponent of Bz or Boverall.
A graphical representation of the network meta-epi-
demiological model can be found in the
Supplementary Appendix (Supplementary Figure 1).
All models are presented in detail in the Appendix.
Sensitivity and subgroup analyses
Additional analyses were conducted to check the sen-
sitivity of the results to the measure of precision of
the observed effect size used as an explanatory factor
(variance, standard error, inverse of variance, or
square root of inverse variance) in the analysis of im-
precise-study effects. We performed two additional
analyses in which we included all networks with
dichotomous outcomes (star and full networks), to
evaluate the impact of studies with small sample
size. These were defined as studies with a total
sample size of less than 200 (as suggested in Zhang
et al.24) or less than 300 (based on the present data;
see Supplementary Appendix for details) participants.
We assessed the robustness of results to the exclusion
of networks with very large or small coefficients com-
pared to the other networks. Such networks may vio-
late the exchangeability assumption underlying the
coefficients across networks. We performed a sensitiv-
ity analysis for the network meta-epidemiological
model using the RR instead of the OR. Evaluation
of the impact of risk of bias items was done separ-
ately for mortality and non-mortality outcomes.5 We
extracted risk of bias information only for a subset of
the networks (relying on previously reported risk of
bias classifications in the remainder of cases, for
which it is possible that different criteria were
used). We therefore performed a sensitivity analysis
that included only networks for which we extracted
data according to our criteria as described in the
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Supplementary Appendix. To check whether different
types of interventions affected the results of the
adjustment for risk of bias items, we excluded net-
works with non-pharmacological interventions from
our analysis.
Model selection and implementation
We evaluated the parsimony of all models according to
the deviance information criterion (DIC), lower values
of which suggest a better compromise between model fit
and model complexity.25 All models were fitted using
Markov chain Monte Carlo simulation in the freely
available software WinBUGS 1.4.3.26 Normal vague
priors were given to location parameters. We assumed
a half-normal prior distribution   Nð0,1Þ with   0
for the between-study heterogeneity standard devi-
ation, , and a uniform ð0,3Þ distribution for the stan-
dard deviation, !, of the imprecise-study effects
coefficients. All results are presented as posterior me-
dians with the 95% credible interval. More technical
details and alternative prior distributions for ! are pre-
sented in the Supplementary Appendix.
Results
Characteristics of included networks of
interventions
The search identified 890 relevant abstracts, of which
276 were assessed as potentially eligible and whose
full articles were screened. After the classification of
studies into networks with and without closed loops,
we ended up with 32 star-shaped networks (613 stu-
dies) suitable for inclusion (see Figure 1 for details of
the search results and selection process). All of the
networks were published after 1999 and cover a
variety of medical fields, as shown in Supplementary
Table 1 (available as Supplementary data at IJE
online). The method of indirect comparison used
were Bucher’s method (known also as the method
of adjusted indirect comparison) (50%), meta-regres-
sion approaches (25%), and Bayesian network meta-
analysis (25%). Twenty-two (69%) of the star-shaped
networks included 10 or more studies, and the
number of treatments compared ranged from 3 to
20. Data about risk of bias in the included studies
were obtained for these 32 star-shaped networks
(available in the original publication, extracted, or
provided by the authors). The number of studies
determined to be at low, unclear, and high risk of
bias for each network are presented in
Supplementary Table 2 (available as Supplementary
data at IJE online). We included 22 star-shaped net-
works with 10 or more studies (a total of 545 studies)
for the independent network-specific adjustment, in
which each network was analysed separately estimat-
ing independent network-specific coefficients.
Adjustment of each network using exchangeable co-
efficients across treatment comparisons yielded
890 abstracts 
identified 614 excluded:
no interventions evaluated
2 treatments compared
no indirect comparisons
discussing/commentary276 full articles124 excluded:
11 comments/letters/case series
78 no/naive indirect comparisons
13 studies ≤ treatments
4 methodological
10 not only RCTs
3 diagnostics/genetics
5 not meta-analyses 152 networks
57 excluded:
13 three treatments
2 subsets of larger networks
1 duplicated publication
22 data not available 
7 without obvious reference 
intervention
7 with overlapping studies
5 not measure with OR or MD
47 star networks 105 full networks
15 excluded:
4 duplicated 
11 without available 
data
32 star networks 
included in the 
analysis
48 eligible full 
networks for the 
sensitivity analysis
Figure 1 Flow chart of the study selection
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similar results and similar model fit to those obtained
with fixed coefficients. We therefore report the latter
as the simpler model, with more precise estimates.
Twenty star-shaped networks (after the exclusion of
networks with overlapping studies) (358 studies) re-
ported dichotomous outcomes measured with OR, and
were included in the meta-epidemiological model. The
remaining 5 star-shaped networks with continuous
data, 4 networks reporting HR (for each included
study), 1 network with rate data as well as 2 net-
works that used RR as effect size measure, were not
synthesized because of the small numbers of net-
works. We further identified 34 full networks (934
studies) with dichotomous outcomes measured with
OR, and 13 full networks (358 studies) with continu-
ous outcomes measured with MD, which we included
in the meta-epidemiological model for imprecise-
study effects. These were combined (after excluding
overlapping networks) with 18 star-shaped networks
with dichotomous data and with 2 star networks with
continuous data, respectively. Only 7 networks (4 star
and 3 full networks) reporting HR were identified and
were therefore not synthesized (see Supplementary
Table 3 for the characteristics of full networks).
Adjustment for risk of bias items
Network-specific effects for the four risk of bias items
did not show any impact on the estimated treatment
effects. Of the 22 networks with 10 or more studies,
60%, 55%, 56%, and 61% resulted in positive coeffi-
cients for allocation concealment, sequence
generation, blinding of patients, and outcome asses-
sors, respectively (see Table 1). None of the coeffi-
cients was statistically significant or close to
significance. The heterogeneity also did not change
substantially, with differences being smaller than
3.5% of the estimated heterogeneity before the
adjustment.
Figure 2 shows the network meta-epidemiological
summary effects from the 20 star-shaped networks
when exchangeable coefficients were assumed across
networks and fixed coefficients within networks. No
evidence is provided for the impact of studies with
high or unclear risk of bias on the relative effective-
ness or safety of the interventions. The between-net-
works standard deviation (!) (on lnðORÞ scale) of the
summary ROR was 0.91 (0.75, 1.09), 0.98 (0.83, 1.18),
1.16 (0.95, 1.43), and 1.15 (0.83, 1.60) for random
sequence generation, allocation concealment, and
blinding of patients and outcome assessors, respect-
ively, and did not change when different prior distri-
butions were used. The meta-epidemiological models
that did not account for between-networks variability
(estimating a fixed coefficient across networks) led to
similar conclusions. The DIC values were similar
before and after the adjustment in almost all ana-
lyses, and changes were smaller than the three-point
threshold that can support differences in model par-
simony (Supplementary Table 4, available as
Supplementary data at IJE online).25 Subgrouping
the networks according to the type of outcome (mor-
tality vs. other) did not change the results (Figure 2).
We also compared the rankings of treatments within
each network as estimated by the meta-epidemiolo-
gical and the unadjusted models. Adjustment for
blinding of patients yielded small differences in the
hierarchy of the treatments in three networks; blind-
ing of outcome assessors and sequence generation af-
fected two networks; and allocation concealment
changed one network. When we analysed only net-
works for which we had assessed the risk of bias in
individual studies (12 networks), the RORs for
random sequence generation, allocation concealment,
and blinding of patients and outcome assessors were
0.83 (0.63, 1.12), 0.97 (0.74, 1.30), 1.07 (0.80, 1.46)
and 1.22 (0.83, 1.88), respectively. Excluding net-
works with non-pharmacological interventions (2 net-
works) yielded the same results as did the primary
analysis.
Adjustment for study precision
Of 22 networks including 10 or more studies, 18
(81.8%) resulted in positive imprecise-study effects
coefficients, implying that imprecise studies exagger-
ated the treatment effects compared to the control
intervention in most of the networks. Eight of the
positive coefficients (36.4%) and 1 of the 4 negative
coefficients showed a large effect of imprecise studies
in the respective networks (accounting for the differ-
ent effect size measures between networks), and were
also statistically significant (see Table 1). In 4 of the 8
networks with positive significant coefficients, the
DIC of the adjusted model was considerably lower
than that of the unadjusted model, showing an im-
portant improvement in model parsimony after the
adjustment (Supplementary Table 3, available as
Supplementary data at IJE online). Heterogeneity
decreased in 13 (40.6%) networks after the adjust-
ment for imprecise-study effects, with a relative
drop ranging from 7.1% to 39.5%; 13 networks
showed a relative increase in heterogeneity, of be-
tween 1.4% and 9.1% (Figure 3a). Figure 3b shows
the corresponding reduction in the comparison-spe-
cific effect sizes, indicating that in most of the net-
works, the relative effects of active or newer
treatments versus the common comparator were
exaggerated in less precise studies. The meta-epi-
demiological summary (ROR) estimate accounting
for between-studies variability in ORs was 1.84
(1.09, 3.32), with between-networks standard devi-
ation, ! ¼ 0.83 (0.41, 1.48) (Figure 4). The model
that ignored the between-networks variability (fixed
coefficient) further increased the precision of the ana-
lysis and resulted in an overall common imprecise-
study effects ROR equal to 1.38 (1.11, 1.70). The
sum of DICs from the unadjusted models for all
star-shaped networks was 1291, which was consider-
ably higher than the DIC of the joint model
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Figure 3 Comparison of (a) between-study standard deviations, and (b) the pooled relative effect sizes of all treatments vs.
the common comparator for all networks with at least 10 studies between the unadjusted model and the model adjusted for
imprecise-study effects. The diagonal lines indicate equality of effects with and without adjustment
Sequence 
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Figure 2 Overall ratios of odds ratios (RORs) for each risk of bias component, derived from the joint analysis and for
subgroups on mortality and non-mortality networks. Outcome assessors were defined as being blinded for all mortality
networks. An ROR larger than 1 indicates that the effect of new or active treatments is exaggerated relative to the control
intervention in studies at high or unclear risk of bias (CrI¼ credible interval)
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(DIC¼ 1276), showing that adjustment led to more
parsimonious models. Comparison of treatment
ranks as estimated from the joint model and the un-
adjusted model for each network showed differences
in treatment classification in three networks. More
specifically, the common comparator interventions of
these networks had a higher rank in the treatment
hierarchy after the adjustment.
Sensitivity analyses
Changing the measure of precision used as covariate for
the adjustment of imprecise-study effects resulted in
slightly different but compatible conclusions. The coef-
ficient for the regression on the standard error was simi-
lar but less precise than in the primary analysis
[ROR¼ 2.01 (1.02, 12.22)]. Using the inverse of vari-
ance or the square root of inverse variance as covariates
gave estimates close to the null value of 1; however, the
model fit and parsimony as conveyed by the DIC values
was much worse for these two models (Supplementary
Table 5, available as Supplementary data at IJE online).
Network 127 resulted in a considerably larger coeffi-
cient compared to those of the other networks, and
might thus violate the exchangeability assumption
(Figure 4). When, excluded, the meta-epidemiological
summary ROR was estimated as 1.62 (1.00, 2.86). When
we performed the analysis (with all star networks) on
the log-risk ratio scale, the overall coefficient was simi-
lar to that of the primary analysis. Lastly, the inclusion
of the 34 full networks in the analysis did not substan-
tially change the magnitude of the summary coeffi-
cient, but did increase the precision of the estimate
[ROR¼ 1.88 (1.43, 2.51)] (Supplementary Table 5,
available as Supplementary data at IJE online). Using
sample size thresholds of 200 and 300 patients, small
trials appeared to exaggerate the ORs for the active or
experimental interventions by on average 26% and 13%,
respectively [RORs 1.26 (1.10, 1.46) and 1.13 (1.00,
1.28)]. When we fitted the meta-epidemiological
model for the 15 networks (2 star and 13 full networks)
using MD as the measure of effect, the coefficient esti-
mate (difference of mean differences) was close to
zero [B¼ 0.02 (–0.34, 2.38)]. The use of alternative
1
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Figure 4 Network-specific coefficients of imprecise-study effects for all networks with dichotomous outcome data, based
on models for the separate analysis of each network and the joint analysis of all networks. A ratio of odds ratios (ROR)
larger than 1 indicates that imprecise studies exaggerate the effect of new or active treatments relative to the control
intervention. (CrI¼ credible interval)
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distributions for the between-networks standard devi-
ation, !, of the coefficients did not affect the results of
any of the analyses.
Association between study size and risk of
bias components
Figure 5 shows the distribution of study variance for
studies at low risk versus high or unclear risk of bias.
Most studies with small variances were assessed as
being at high or unclear risk of bias for sequence gen-
eration and allocation concealment. The opposite was
observed for blinding of patients and outcome asses-
sors, where more precise studies were more often ad-
equately blinded.
Discussion
To our knowledge, this is the first network meta-
epidemiological study assessing the impact of
imprecise-study effects and of four risk of bias items
on treatment effects. Previous empirical studies of
pairwise meta-analyses investigating the association
between risk of bias items and treatment effects
have yielded inconsistent conclusions. Balk et al.28
found that poor randomization, allocation conceal-
ment, and lack of blinding did not affect the esti-
mated treatment effects, which agrees with our
findings. However, other meta-epidemiological stu-
dies4,29 have shown that studies with inadequate con-
duct of these three risk of bias items tended to
exaggerate the treatment effects. Siersma et al.30
found that random generation of sequence allocation
was an important predictor of trial results. In contrast
to our study, as well as that of Balk et al.,28 the results
presented by Wood et al.5 imply that subjective out-
comes are affected by inadequate allocation conceal-
ment and lack of blinding of patients more than all-
cause mortality and other objective outcomes. Also,
Hrobjartsson et al.31 found that blinding of outcome
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Figure 5 Histograms showing the distributions of variance (of lnðORÞ) for individual studies classified according to each
risk of bias category for random sequence generation (a), allocation concealment (b), and blinding of patients (c) and
outcome assessors (d)
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assessors affected the treatment effect estimates in
trials with binary subjective outcomes.
A recent combined analysis of seven meta-epidemio-
logical studies7 resulted in marginally exaggerated
intervention effects in trials with inadequate or un-
clear conduct of random sequence generation, alloca-
tion concealment, and double-blinding. Our study’s
finding of weaker associations might be explained
by limited power; our set of network meta-analyses
included on average 31% fewer trials compared to
Savovic et al.7 Moreover, because network meta-ana-
lysis is a novel and resource-demanding methodology,
investigators undertake it primarily to answer ques-
tions for which they know many valid studies exist.
Additionally, the lack of association between risk of
bias items and treatment effects might be due to
random misclassification resulting from the different
approaches and criteria used by the original authors
of each network to assess the risk of bias in trials.
However, in the networks for which we ourselves ex-
tracted risk of bias data, the RORs for the four risk of
bias items did not differ from the RORs for which we
did not extract such data. Our data do not highlight a
clear association between study size and study qual-
ity, which was present in the analyses of Kjaergard
et al.32 and Nuesch et al.2
In our analysis, we considered trials at unclear and
high risk of bias as having a similar effect. This as-
sumption can be relaxed in models that attribute a
probability of being at high risk to studies of unclear
risk.13 However, in our dataset, the number of studies
at high risk of bias was very small, and such models
do not have enough power to estimate effects. When
risk of bias characteristics are unavailable, study pre-
cision could be considered as a proxy for them, but
interpretation of the results in this case needs careful
consideration. Furthermore, it is possible that other
types of biases operate, such as selective outcome re-
porting and attrition bias, for which we did not
account.
Our analyses illustrated an important impact of
study precision on the results of network meta-
analysis with dichotomous outcomes. If some com-
parisons in the network are informed by less precise
estimates than others, inconsistency can occur.33
Consequently, investigators should routinely evaluate
the distribution of variance across comparisons
included in a network, and should consider study pre-
cision as a possible source of inconsistency. In the
present study we included only star-shaped networks,
which do not allow statistical evaluation of the as-
sumption of consistency.
Adjustment for imprecise studies can be done rou-
tinely through meta-regression. The models presented
here rely on a range of study variances on which the
coefficients are estimated. Estimation of regression
coefficients is challenging when comparisons include
studies of similar precision, especially in models with
independent coefficients. The estimated intercept can
be seen as the relative treatment effect when variance
approximates zero. Because zero is outside the range
of observed variances, it might be more interpretable
to center the precision variable at the smallest
observed variance. In some circumstances researchers
may need to extrapolate beyond the range of observed
precisions (e.g. if all the studies are very imprecise);
caution is needed in doing so. An association between
effect size and precision can be heuristically under-
stood as small studies providing different results
from larger studies, although sample size is only one
of the components influencing the variance of the
observed effect size. It is not possible to define what
constitutes an imprecise or ‘small’ study unless one
restricts its definition to a specific application and
outcome (such as in the study by Nuesch et al.2).
Continuous measures are often used for subjective
and secondary outcomes, and should therefore be
more prone to selective outcome reporting resulting
in a pronounced association between variance and
study effect. However, we did not observe important
imprecise-study effects in networks with continuous
outcomes. This might be due to low power (only 16
networks with continuous data were identified) or to
the larger heterogeneity in continuous effect
measures.
In our analysis, we used the variance of the
observed effect size as an explanatory variable for
the between-studies variation of the treatment
effect. A limitation of this approach for dichotomous
outcomes is that because the observed log-odds ratio
and its variance are both functions of the true log-
odds ratio, an inherent correlation can be induced.
However, use of the exact binomial likelihood, as
we were able to do whenever arm-level data were
available, mitigates this dependence.33,34
Conclusions
In this network meta-epidemiological study of 32
star-shaped networks comprising 613 trials from sev-
eral medical fields, we found evidence that imprecise
studies produce larger effects than do more precise
studies. However, we found no evidence supporting
an association of effect size with other previously
identified indicators of bias, such as random sequence
generation, allocation concealment, and blinding.
Subgroup-specific coefficients for specific types of out-
comes estimated in our study could be used to form
informative priors and adjust treatment effects in
future network meta-analysis studies.13
As with conventional pairwise meta-analysis, net-
work meta-analysis can be affected by the tendency
of imprecise studies to overestimate the effectiveness
or safety of the treatments, and this should be taken
into account when conducting such an analysis. In
this case, adjusted results from network meta-regres-
sion models should be presented extrapolated to the
most precise study in the network.22 Modified funnel
EFFECTS OF STUDY PRECISION AND RISK OF BIAS IN NETWORKS OF INTERVENTIONS 1129
plots can also be used for this purpose,34 and selection
models can be fit in case the association between
study size and effect is due to publication or reporting
bias.35
Supplementary Data
Supplementary Data are available at IJE online.
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Identifying clinical trial characteristics influencing
intervention effect estimates is crucial. Trials with
such characteristics may lead to underestimating or
overestimating true intervention effects. To assess risk
of bias in randomized trials, the Cochrane Collaboration
has developed a tool based on theoretical as well as
empirical considerations regarding the impact of risk
factors for bias.1 Empirical evidence comes from
meta-epidemiology. This approach involves use of a col-
lection of meta-analyses to compare intervention effect
estimates among trials with and without a particular
characteristic. More recently, meta-meta-epidemiology,
which combines data from several meta-epidemiolo-
gical studies, has been developed.2,3 In this issue of the
journal, Chaimani et al.4 propose network meta-epidemi-
ology as an interesting new approach: meta-epidemiology
in the framework of networks of trials, thus exploiting the
assumption that the impact of risk factors is similar
within networks.
Table 1 compares the methodological features of each
approach. Each approach has pros and cons related to
differences in data sources and assessment of risk fac-
tors. Meta-meta-epidemiology involves larger and prob-
ably more representative collections of meta-analyses
than meta-epidemiology or network meta-epidemi-
ology. In meta-epidemiology, an important restriction
is that informative meta-analyses must include at
least one trial with and one without the risk factor of
interest. Moreover, a minimum number of trials per
meta-analysis may be required, depending on how het-
erogeneity is modelled and whether multivariable ana-
lyses are undertaken. In network meta-epidemiology,
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